News
ROCKVILLE, Md., May 26, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen ...
This presentation highlights data from one institution participating in ICT’s IRB approved trial with GCC19CART for patients with R/R mCRC conducted at multiple institutions in China.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback